Promoter Polymorphism (rs3755724, -55C/T) of Tissue Inhibitor of Metalloproteinase 4 (TIMP4) as a Risk Factor for Kawasaki Disease with Coronary Artery Lesions in a Korean Population

Kawasaki disease (KD) is an acute febrile vasculitis that predominantly affects infants and young children. Tissue inhibitors of matrix metalloproteinases (TIMPs) comprise a family of four members, of which TIMP4 is characterized by its restriction to cardiovascular structures. In KD pathophysiology, TIMP4 is considered to be involved in the development of coronary artery lesions (CALs). Therefore, this study investigated single-nucleotide polymorphisms (SNPs) of the TIMP4 gene as risk factors for KD with CALs in Korean children. To observe this association, two SNPs (rs3755724, -55C/T, promoter; rs17035945, 3′-untranslated region) were genotyped in TIMP4 using direct sequencing. There were no SNPs in the coding region of TIMP4, and two SNPs were selected in the exon and promoter regions. This study recruited 250 control and 101 KD subjects. For data analysis, SNPStats, SNPAnalyzer, and Helixtree programs were used. These SNPs were not associated with KD. However, in the recessive model, a significant association was found between rs3755724 and the development of CALs in KD (P = 0.02; odds ratio, 0.31; 95% confidence interval, 0.11–0.85). The minor allele (C) of rs3755724 showed the susceptibility of CALs to risk in KD patients. These results suggest that TIMP4 is related to the development of KD with CALs in Korean children.

[1]  S Masutani,et al.  Circulating Matrix Metalloproteinases and Their Inhibitors in Patients with Kawasaki Disease , 2001, Circulation.

[2]  I. Sekine,et al.  Elevated serum levels of matrix metalloproteinase‐9 (MMP‐9) in Kawasaki disease , 2001, Clinical and experimental immunology.

[3]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[4]  K. Lee,et al.  Association of TIMP-4 gene polymorphism with the risk of osteoarthritis in the Korean population , 2008, Rheumatology International.

[5]  F. Baquero-Artigao,et al.  Coronary Involvement in Infants with Kawasaki Disease Treated with Intravenous γ-Globulin , 2007, Pediatric Cardiology.

[6]  E. Vuorio,et al.  Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology , 2006, Histochemistry and Cell Biology.

[7]  Youn Jung Kim,et al.  Assessment of Relationship between Fyn-related Kinase Gene Polymorphisms and Overweight/Obesity in Korean Population. , 2008, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology.

[8]  Joan Valls,et al.  SNPStats: a web tool for the analysis of association studies , 2006, Bioinform..

[9]  R. Kizek,et al.  Matrix metalloproteinases. , 2010, Current medicinal chemistry.

[10]  Gillian Murphy,et al.  Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.

[11]  K. Yabuta,et al.  Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. , 1990, Clinical immunology and immunopathology.

[12]  Walter R Wilson,et al.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association , 2004, Pediatrics.

[13]  S. Crawford,et al.  Systemic Arterial Expression of Matrix Metalloproteinases 2 and 9 in Acute Kawasaki Disease , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[14]  E. Vuorio,et al.  Characterization of the murine Timp4 gene, localization within intron 5 of the synapsin 2 gene and tissue distribution of the mRNA. , 2002, Biochimica et biophysica acta.

[15]  L. Rubin,et al.  Prevalence of coronary artery lesions on the initial echocardiogram in Kawasaki syndrome. , 2006, Archives of pediatrics & adolescent medicine.

[16]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[17]  T. Matsuyama,et al.  Tissue inhibitor of metalloproteinases‐1 and matrix metalloproteinase‐3 in Japanese healthy children and in Kawasaki disease and their clinical usefulness in juvenile rheumatoid arthritis , 1999, Pediatrics international : official journal of the Japan Pediatric Society.

[18]  V. Nerurkar,et al.  Elevated Levels of Matrix Metalloproteinase 9 and Tissue Inhibitor of Metalloproteinase 1 during the Acute Phase of Kawasaki Disease , 2003, Clinical Diagnostic Laboratory Immunology.

[19]  Toshiro Hara,et al.  Genetic Analysis of MMP Gene Polymorphisms in Patients With Kawasaki Disease , 2008, Pediatric Research.